In the last trading session, 2.3 million shares of the Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) were traded, and its beta was 0.00. Most recently the company’s share price was $8.67, and it changed around $0.09 or 1.05% from the last close, which brings the market valuation of the company to $1.15B. MRVI currently trades at a discount to its 52-week high of $16.62, offering almost -91.7% off that amount. The share price’s 52-week low was $4.52, which indicates that the current value has risen by an impressive 47.87% since then. We note from Maravai LifeSciences Holdings Inc’s average daily trading volume that its 10-day average is 3.16 million shares, with the 3-month average coming to 2.69 million.
Maravai LifeSciences Holdings Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.58. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 6 rate it as Overweight. Among the rest, 3 recommended MRVI as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Maravai LifeSciences Holdings Inc is expected to report earnings per share of -$0.03 for the current quarter.
Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) trade information
Instantly MRVI has showed a green trend with a performance of 1.05% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently up 32.37% year-to-date, but still up 6.25% over the last five days. On the other hand, Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) is 8.10% up in the 30-day period. We can see from the shorts that 7.35 million shares have been sold at a short interest cover period of 1.9 day(s).
The consensus price target as assigned by Wall Street analysts is $23.5, which translates to bulls needing to increase their stock price by 63.11% from its current value. Analyst projections state that MRVI is forecast to be at a low of $22 and a high of $25.
Maravai LifeSciences Holdings Inc (MRVI) estimates and forecasts
Maravai LifeSciences Holdings Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -11.17 percent over the past six months and at a -133.33% annual growth rate that is well below the industry average of 16.40%. The year-over-year growth rate is expected to be -5.80%, down from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of $60.55 million in revenue for the current quarter. 9 analysts expect Maravai LifeSciences Holdings Inc to make $66.95 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $79.03 million and $68.91 million respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -23.40%. Forecasts for the next quarter put sales growth at -2.80%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -37.53%.
MRVI Dividends
Maravai LifeSciences Holdings Inc’s next quarterly earnings report is expected to be released around May 06 and May 10.
Maravai LifeSciences Holdings Inc (NASDAQ:MRVI)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.37% of Maravai LifeSciences Holdings Inc shares, and 102.61% of them are in the hands of institutional investors. The stock currently has a share float of 105.10%. Maravai LifeSciences Holdings Inc stock is held by 307 institutions, with GTCR, LLC being the largest institutional investor. By Jun 29, 2023, it held 16.43% of the shares, which is about 21.68 million shares worth $269.5 million.
Massachusetts Financial Services Co., with 8.46% or 11.15 million shares worth $138.65 million as of Jun 29, 2023, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund were the top two Mutual Funds as of Jun 29, 2023. The former held 3.51 million shares worth $43.63 million, making up 2.66% of all outstanding shares. On the other hand, Vanguard Small-Cap Index Fund held roughly 2.89 million shares worth around $35.98 million, which represents about 2.19% of the total shares outstanding.
